IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform. The company's approach focuses on targeting cancer cells and immune-suppressive cells within the tumor microenvironment. Its lead candidate, IO102-IO103, targets indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1) and is currently in phase 3 clinical trials for melanoma, with phase 2 studies underway for lung, head and neck, and melanoma cancers.
The company's pipeline includes IO112, a therapeutic vaccine candidate containing an Arginase 1-derived peptide designed to treat tumors with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. IO Biotech also develops IO170, a TGFß1 vaccine for solid tumors. As a clinical-stage company, the organization does not generate product revenues and remains dependent on capital raising and partnerships to fund development activities.
Incorporated in Delaware in 2014, IO Biotech maintains its headquarters in Copenhagen, Denmark, with approximately 80 full-time employees. The company is listed on Nasdaq and operates primarily in the biopharmaceutical development sector.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.45 | $-1.45 | +26.8% | |
| 2023 | $-1.98 | $-1.98 | +20.2% | |
| 2022 | $-2.48 | $-2.48 | — | |
| 2021 | — | — | — |